Overview

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Status:
Active, not recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

ONO Pharmaceutical Co.
Ono Pharmaceutical Co. Ltd

Treatments:

Bevacizumab
Fluorouracil
Leucovorin
Nivolumab
Oxaliplatin